Please use this identifier to cite or link to this item:
Title: Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol
Authors: Maduro Bouillet, Leoneide Erica
Dias, Mariana Oliveira
Dorigo, Natalia Alves
Moura, Andrew Douglas
Russell, Bruce
Nosten, Francois
Renia, Laurent
Braga, Erika Martins
Gazzinelli, Ricardo Tostes
Rodrigues, Mauricio M.
Soares, Irene S. [UNIFESP]
Bruna-Romero, Oscar
Universidade Federal de Minas Gerais (UFMG)
Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Fiocruz MS
Agcy Sci Technol & Res
Shoklo Malaria Res Unit
Churchill Hosp
Mahidol Univ
Issue Date: 1-Sep-2011
Publisher: Amer Soc Microbiology
Citation: Infection and Immunity. Washington: Amer Soc Microbiology, v. 79, n. 9, p. 3642-3652, 2011.
Abstract: Apical membrane antigen 1 (AMA-1) is an invasion-related Plasmodium antigen that is expressed during both intracellular and extracellular asexual stages of the parasite's life cycle, making it an ideal target for induction of humoral and cellular immune responses that can protect against malaria. We show here that when it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant human type 5 adenovirus (Ad), intense and long-lasting Plasmodium vivax AMA-1-specific antibody responses (including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in immunized mice. Memory T cells displayed both central (CD44(hi) CD62L(hi)) and effector (CD44(hi) CD62L(lo)) phenotypes, with the central memory phenotype prevailing (56% of AMA-1-specific proliferating cells). Considering the main traits of the memory immune responses induced against AMA-1, this particular sequence of immunogens (P followed by Ad), but no others (Ad/Ad, Ad/P, or P/P), displayed an optimal synergistic effect. These results give further support to the need for preclinical studies of P. vivax vaccine candidate AMA-1 administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.
ISSN: 0019-9567
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
WOS000293891000016.pdf2.26 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.